Theravance Biopharma, Inc. and Mylan Inc. have partnered for the development and commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases. TD-4208 has shown positive results in COPD in multiple Phase II studies, and the design of the Phase III registrational program is underway and anticipated to begin this year. Theravance will lead the U.S. registrational ...